Humana (NYSE:HUM) Stock Price Down 9.1% – Should You Sell?

Shares of Humana Inc. (NYSE:HUM – Get Free Report) dropped 9.1% during mid-day trading on Wednesday. The company traded as low as $409.25 and last traded at $403.12. 605,237 shares changed hands during trading, a decline of 63% from the average session volume of 1,647,300 shares. The stock had previously closed at $443.34.

Key Humana News

Here’s some of the latest news about HUM:

  • Positive Sentiment: Zacks Research raised its FY2026 EPS estimate to $9.50 from $9.05 and its Q1 2028 estimate to $11.72 from $11.53. Morgan Stanley also raised its price target to $475 from $370, though it kept an “equal weight” rating. MarketBeat analyst estimate report Morgan Stanley rating report
  • Neutral Sentiment: Analyst revisions were mixed: Zacks lowered its Q3 2028 EPS estimate to $6.38 from $6.58, despite raising its Q1 2028 and FY2026 forecasts. Its FY2026 estimate also remains below the cited consensus of $9.66. MarketBeat analyst estimate report
  • Negative Sentiment: Healthcare insurers, including Humana, have faced pressure amid a new Medicare for All proposal, which raises concerns about the longer-term outlook for private health plans. MarketWatch article on healthcare shares

Analysts Set New Price Targets

HUM has been the subject of a number of analyst reports. Citigroup assumed coverage on Humana in a research report on Friday, October 9th. They issued a “buy” rating for the company. Oppenheimer upped their target price on shares of Humana from $475.00 to $525.00 and gave the stock an “outperform” rating in a research note on Monday, October 12th. William Blair assumed coverage on Humana in a report on Monday. They set an “outperform” rating on the stock. Bank of America upgraded Humana from a “neutral” rating to a “buy” rating and set a $500.00 price objective on the stock in a research note on Wednesday, July 29th. Finally, Deutsche Bank began coverage on shares of Humana in a report on Thursday, July 30th. They issued a “hold” rating on the stock. One research analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating, eight have issued a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $491.74.

Check Out Our Latest Analysis on Humana

Humana Stock Performance

The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.65 and a current ratio of 1.65. The business’s 50-day moving average is $409.87 and its 200 day moving average is $321.41. The company has a market cap of $46.84 billion, a PE ratio of 37.94, a PEG ratio of 1.84 and a beta of 0.65.

Humana (NYSE:HUM – Get Free Report) last issued its earnings results on Friday, November 6th. The insurance provider reported ($0.70) earnings per share for the quarter, beating the consensus estimate of ($1.00) by $0.30. Humana had a return on equity of 8.50% and a net margin of 0.81%. The company had revenue of $41.16 billion during the quarter, compared to analysts’ expectations of $40.87 billion. During the same period in the prior year, the business posted $3.24 EPS. Humana’s quarterly revenue was up 26.1% compared to the same quarter last year. Humana has set its FY 2026 guidance at 9.500- EPS. On average, equities research analysts predict that Humana Inc. will post 9.66 EPS for the current fiscal year.

Humana Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, January 29th. Investors of record on Thursday, December 24th will be issued a dividend of $0.8850 per share. This represents a $3.54 dividend on an annualized basis and a dividend yield of 0.9%. The ex-dividend date is Thursday, December 24th. Humana’s dividend payout ratio is currently 34.44%.

Insider Activity at Humana

In other news, insider Joseph Ventura sold 5,495 shares of Humana stock in a transaction dated Monday, November 9th. The shares were sold at an average price of $433.85, for a total transaction of $2,384,005.75. Following the sale, the insider owned 21,910 shares of the company’s stock, valued at approximately $9,505,653.50. The trade was a 20.05% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.20% of the company’s stock.

Institutional Investors Weigh In On Humana

Several hedge funds have recently made changes to their positions in the company. Johnson Financial Group Inc. purchased a new stake in Humana in the second quarter worth about $26,000. Trust Co. of Vermont bought a new position in shares of Humana during the 2nd quarter valued at $28,000. Bogart Wealth LLC boosted its position in Humana by 192.0% in the second quarter. Bogart Wealth LLC now owns 73 shares of the insurance provider’s stock worth $29,000 after purchasing an additional 48 shares during the last quarter. MidFirst Bank purchased a new stake in Humana during the second quarter valued at approximately $35,000. Finally, Highland Investment Advisors LLC bought a new position in Humana in the 2nd quarter worth $43,000. 92.38% of the stock is currently owned by institutional investors.

Humana Company Profile

(Get Free Report)

Humana Inc. is a U.S. health and wellness company that provides health insurance and healthcare services. Its insurance offerings include Medicare Advantage, Medicare Supplement and prescription drug plans, as well as Medicaid and employer-sponsored plans. The company also provides care through CenterWell, its healthcare services brand, which includes primary care, home health and pharmacy services. Its insurance and care offerings are available in markets across the United States, with availability varying by product and location.

Featured Articles

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.